Evaluation of Viral Suppression in Paediatric Populations: Implications for the Transition to Dolutegravir-Based...

Global efforts to combat Acquired Immunodeficiency Syndrome (AIDS) face significant hurdles in younger demographics where mortality remains disproportionately high due to complex biological and social factors. Prior research has shown that children account for approximately 15% of all AIDS-related fatalities worldwide, despite representing a smaller fraction of the total infected population. In Cameroon, this burden escalates to 25%, suggesting that local healthcare systems struggle with unique barriers to effective treatment and long-term survival. Poor virological response often stems from suboptimal drug formulations, inconsistent adherence, or delayed adoption of potent therapeutic agents like integrase inhibitors. Establishing robust monitoring frameworks is essential for identifying which subgroups fail to achieve undetectable levels of Human Immunodeficiency Virus (HIV) within the national treatment program. Comprehensive data on age-specific outcomes are required to refine clinical guidelines and ensure that the most vulnerable patients receive optimized care. This absence of evidence motivated a comprehensive evaluation of treatment outcomes across diverse age brackets within the Cameroonian national healthcare infrastructure to inform future policy.

This research evaluates the prevalence and determinants of paediatric viral suppression among a representative cohort of Cameroonian children, adolescents, and young adults receiving lifelong therapy. Investigators sought to quantify how effectively different age groups respond to various Antiretroviral Therapy (ART) protocols while identifying specific barriers to clinical success. The study specifically examines the impact of transitioning from older Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-based regimens to modern Dolutegravir (DTG)-based treatments across nine distinct reference laboratories. Identifying specific predictors of non-suppression allows for targeted interventions in populations at the highest risk of treatment failure and subsequent disease progression. Researchers aimed to provide data-driven insights to support the national scale-up of optimized drug combinations that align with international health standards. The analysis focuses on aligning local clinical outcomes with the ambitious 95-95-95 targets set by global health organizations for epidemic control. Understanding these dynamics is vital for reducing the high mortality rates observed in the Central African region.

Researchers conducted a multicentric, cross-sectional investigation utilizing data from nine reference laboratories to ensure a nationally representative sample of the Cameroonian paediatric population. The study population included 7,558 individuals categorized into children under ten, adolescents aged ten to nineteen, and young adults up to twenty-four years old. Data collection spanned from December 2023 to March 2024, capturing a snapshot of current clinical performance during the transition to new drug classes. Viral Load (VL) was measured using standardized molecular assays to define suppression as having fewer than 1000 HIV-RNA copies per milliliter of plasma. A conditional backward stepwise regression model served as the primary statistical tool for identifying independent predictors of virological outcomes while controlling for confounding variables. The analysis compared outcomes between Dolutegravir (DTG), Efavirenz (EFV), Nevirapine (NVP), Lopinavir/ritonavir (LPV/r), and Atazanavir/ritonavir (ATV/r) regimens to determine relative efficacy. This rigorous approach allowed for a granular assessment of how drug selection influences patient health across different developmental stages.

Overall paediatric viral suppression reached 82.3% across the entire study population, which remains significantly below the 95% global target required for epidemic control. Significant age-related disparities emerged, with children under ten achieving only 67.3% success compared to 86.5% in young adults, reflecting a clear developmental gradient. Individuals on DTG-based regimens exhibited a higher suppression rate of 85.1% compared to only 65.6% for those remaining on protease inhibitor-based combinations. Females demonstrated superior virological outcomes at 85.8% versus 78.2% in their male counterparts, suggesting potential differences in adherence or biological response to therapy. Longitudinal data indicated that undetectable levels remained stable for 24 months but declined significantly to 80% by the 36-month mark after starting treatment. Regression analysis identified younger age, longer therapy duration, and the use of alternative anchor drugs as the primary independent predictors of virological failure. These findings highlight the specific patient subgroups that require intensified monitoring and support to achieve optimal health outcomes.

Achieving the 95% viral suppression target requires urgent prioritization of younger paediatric cohorts who currently lag behind their older peers in virological control. The findings underscore the necessity of accelerating the transition to DTG-based regimens to improve clinical outcomes and reduce the risk of drug resistance. Healthcare providers must address the observed decline in virological control after three years of therapy to ensure long-term treatment success and prevent clinical rebound. Gender-specific strategies might be required to close the gap between male and female response rates observed in this large national cohort. Future interventions should focus on optimizing the nucleoside reverse transcriptase inhibitor backbone, specifically favoring the combination of Tenofovir Disoproxil Fumarate and Lamivudine (TDF/3TC). These data provide a pivotal roadmap for eliminating paediatric AIDS by refining national antiretroviral guidelines and improving drug access across Cameroon. Implementing these evidence-based changes could significantly reduce the disproportionate mortality burden currently faced by children in the region.